# ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis

> **NCT05725213** · — · COMPLETED · sponsor: **Galderma Laboratorium GmbH** · enrollment: 224 (actual)

## Conditions studied

- Actinic Keratoses

## Interventions

- **DRUG:** Metvix® 160 mg/g Creme

## Key facts

- **NCT ID:** NCT05725213
- **Lead sponsor:** Galderma Laboratorium GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-01
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 224 (ACTUAL)
- **Last updated:** 2024-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05725213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05725213, "ADL-PDT Under Routine Clinical Conditions in Patients With Actinic Keratosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05725213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*